Laboratorios Farmaceuticos Rovi, S.A.

LSE:0ILL Stock Report

Market Cap: €3.3b

Laboratorios Farmaceuticos Rovi Future Growth

Future criteria checks 5/6

Laboratorios Farmaceuticos Rovi is forecast to grow earnings and revenue by 20.5% and 12% per annum respectively. EPS is expected to grow by 20.5% per annum. Return on equity is forecast to be 29.1% in 3 years.

Key information

20.5%

Earnings growth rate

20.5%

EPS growth rate

Pharmaceuticals earnings growth19.4%
Revenue growth rate12.0%
Future return on equity29.1%
Analyst coverage

Good

Last updated08 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0ILL - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20269822501902417
12/31/20258311891561967
12/31/20247931681521705
9/30/202479916564126N/A
6/30/20247781483590N/A
3/31/202477913845104N/A
12/31/202383017058113N/A
9/30/202383719760120N/A
6/30/202381818661121N/A
3/31/2023814194104158N/A
12/31/2022818200186238N/A
9/30/2022761176144182N/A
6/30/2022739183192232N/A
3/31/2022724182190229N/A
12/31/2021649153109149N/A
9/30/2021581113145189N/A
6/30/202151982105149N/A
3/31/2021450713172N/A
12/31/202042061747N/A
9/30/202041355-37-7N/A
6/30/202039553-52-27N/A
3/31/202040046-34-7N/A
12/31/201938139-50-9N/A
9/30/201935533-396N/A
6/30/201933427-3112N/A
3/31/201931018-383N/A
12/31/201830318-189N/A
9/30/201829116-138N/A
6/30/20182839N/A16N/A
3/31/201828418N/A30N/A
12/31/201727617N/A18N/A
9/30/201727722N/A21N/A
6/30/201727524N/A25N/A
3/31/201727223N/A24N/A
12/31/201626526N/A46N/A
9/30/201626025N/A44N/A
6/30/201625424N/A38N/A
3/31/201624623N/A40N/A
12/31/201524620N/A29N/A
9/30/201524221N/A22N/A
6/30/201524323N/A27N/A
3/31/201524125N/A29N/A
12/31/201423824N/A23N/A
9/30/201423024N/A30N/A
6/30/201422424N/A28N/A
3/31/201422124N/A20N/A
12/31/201321823N/A30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0ILL's forecast earnings growth (20.5% per year) is above the savings rate (2.1%).

Earnings vs Market: 0ILL's earnings (20.5% per year) are forecast to grow faster than the UK market (14.6% per year).

High Growth Earnings: 0ILL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 0ILL's revenue (12% per year) is forecast to grow faster than the UK market (3.6% per year).

High Growth Revenue: 0ILL's revenue (12% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0ILL's Return on Equity is forecast to be high in 3 years time (29.1%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y